This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
The antibody-drug conjugate trastuzumab deruxtecan might become a promising new treatment option for patients with metastatic HER2-positive breast cancer whose disease has progressed after multiple therapies. In a phase II trial, the drug was associated with a high objective response rate and long median progression-free survival, although some patients developed serious side effects.
- ©2020 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
February 2020
Volume 10, Issue 2
Volume 10, Issue 2
Novel ADC Solidifies Role in Breast Cancer
Jump to section
Advertisement